What is EnhanceMD?
EnhanceMD (enhance.md) is a telehealth platform offering GLP-1 weight loss medications alongside NAD+ therapy — making it one of the few mid-tier clinics with meaningful coverage in both categories. Their most distinctive feature is aggressive intro pricing: semaglutide injection at $49 for the first month and tirzepatide injection at $99 for the first month. This positions EnhanceMD as one of the lowest-barrier entry points to physician-supervised GLP-1 therapy currently available.
Beyond the intro offer, EnhanceMD's ongoing rates — $212/month for semaglutide and $280/month for tirzepatide — are in the higher tier of the market. The platform's clear strength is for patients who want to trial GLP-1 therapy without committing to a high monthly cost upfront, or for patients primarily seeking affordable NAD+ supplementation ($84/month oral) alongside a GLP-1 option.
The 4.2 Trustpilot rating reflects solid patient satisfaction — not market-leading, but meaningfully positive.
Treatments Offered by EnhanceMD
NAD+ — Oral & Injectable
EnhanceMD's oral NAD+ at $84/month ($1,008/year) is one of the more affordable telehealth NAD+ options available — making it practical for patients interested primarily in NAD+ for energy and longevity rather than GLP-1 weight loss. For patients who want higher bioavailability, injectable NAD+ is available at $169/month ($2,028/year). NAD+ functions as a critical cofactor in cellular energy metabolism; declining NAD+ levels are associated with aging, and supplementation is used to support mitochondrial function and cognitive energy.
Semaglutide — Injectable
EnhanceMD's semaglutide injection at $49 for the first month is one of the lowest intro prices in the GLP-1 telehealth category. After the first month, pricing reverts to $212/month ($2,381/year). Semaglutide is a GLP-1 receptor agonist with substantial clinical evidence for weight loss — the STEP 1 trial demonstrated a mean 14.9% body weight reduction over 68 weeks. EnhanceMD's semaglutide protocol involves weekly subcutaneous injection with physician oversight and compounding pharmacy fulfillment.
Tirzepatide — Injectable
Tirzepatide at $99 for the first month (then $280/month, $3,179/year) follows the same intro pricing structure. Tirzepatide is a dual GIP/GLP-1 receptor agonist that outperformed semaglutide in the SURMOUNT-1 trial with a mean 22.5% body weight reduction over 72 weeks. At $99 for first-month access, EnhanceMD is one of the most affordable intro options for tirzepatide among telehealth providers.
Understanding EnhanceMD's Intro Pricing
The $49 and $99 first-month prices apply to the initial month only. Month 2 onward, semaglutide is $212/mo and tirzepatide is $280/mo. For long-term GLP-1 use, compare ongoing rates against Maximus ($132.99/mo sema), Tonik ($149/mo sema), or Oak ($183/mo flat). For a low-cost trial month before committing to a protocol, EnhanceMD's intro offer is hard to beat.
EnhanceMD Pricing
EnhanceMD Protocol Pricing (2026)
Who EnhanceMD is Best For
- Patients who want to trial GLP-1 therapy at the lowest possible entry cost — $49/mo semaglutide or $99/mo tirzepatide first month is hard to beat
- Patients seeking affordable telehealth NAD+ — $84/month oral NAD+ is one of the lower prices in the supervised category
- Anyone who wants both GLP-1 and NAD+ from a single provider without managing two separate clinics
- Patients who are unsure whether GLP-1 therapy is right for them and want to test it before committing to a higher monthly cost
Who Should Look Elsewhere
- Long-term GLP-1 patients who prioritize ongoing monthly cost — Maximus ($132.99/mo), Tonik ($149/mo), and Oak ($183/mo flat) all have lower recurring semaglutide rates than EnhanceMD's $212/mo
- Patients who need testosterone, BPC-157, PT-141, or a broad peptide formulary — EnhanceMD covers GLP-1 and NAD+ only
- Patients who want injectable NAD+ at the lowest price — Tonik's $104/mo injectable NAD+ is cheaper than EnhanceMD's $169/mo
- Patients who need semaglutide oral — EnhanceMD offers injectable only
Pros
- $49 first-month semaglutide — one of the lowest entry prices in GLP-1 telehealth
- $99 first-month tirzepatide — accessible intro to the more potent GLP-1 option
- NAD+ oral from $84/mo — solid value for telehealth-supervised NAD+
- Multi-compound: GLP-1 + NAD+ from one provider
- 4.2 Trustpilot — positive patient satisfaction track record
- Physician-supervised with compounding pharmacy fulfillment
Cons
- Ongoing GLP-1 pricing is high — $212/mo sema and $280/mo tirz after month 1
- Limited formulary — no testosterone, BPC-157, or other peptides
- No oral semaglutide option
- Intro pricing advantage disappears after month 1 vs. competitors
EnhanceMD Patient Reviews
EnhanceMD's 4.2 Trustpilot rating reflects a positive patient experience. Reviews frequently mention smooth onboarding, responsive support, and effective treatment outcomes. The intro pricing model attracts a high volume of first-time GLP-1 patients, and the reviews suggest the transition to ongoing pricing is managed transparently. The rating is solid though not exceptional — competitive clinics like Oak (4.6) and Tonik have higher scores, but EnhanceMD's multi-compound offering and extremely low entry price explain much of its appeal despite the moderate ongoing cost.
Check current reviews at Trustpilot →
EnhanceMD vs Competitors
vs Oak ($183/mo sema flat): Oak's ongoing semaglutide rate is lower than EnhanceMD's $212/mo. After month 1, Oak is a better long-term value for semaglutide. EnhanceMD wins for month-1 cost and for patients who want NAD+ bundled in.
vs Tonik ($149/mo sema, $104/mo NAD+): Tonik is cheaper for both semaglutide and injectable NAD+ on an ongoing basis, and also offers tirzepatide at $229/mo vs EnhanceMD's $280/mo. EnhanceMD wins only on intro pricing and for patients who prefer $84/mo oral NAD+ over $104/mo injectable NAD+.
vs Maximus ($99.99 intro sema): Maximus' $99.99 intro for semaglutide is double EnhanceMD's $49, and ongoing Maximus sema ($132.99/mo) is significantly cheaper than EnhanceMD's $212/mo. Maximus wins on long-term value; EnhanceMD wins if NAD+ access is a requirement alongside GLP-1.
See: Full semaglutide provider comparison → · Full NAD+ provider comparison →
Our Verdict on EnhanceMD
EnhanceMD occupies a specific niche: patients who want to start GLP-1 or NAD+ therapy with minimum upfront commitment. The $49 first-month semaglutide and $99 first-month tirzepatide are genuinely market-leading intro prices. For patients curious about GLP-1 therapy but hesitant to commit to $150–$250/month before knowing how they'll respond, EnhanceMD removes that barrier almost entirely.
The limitation becomes clear after month 1: at $212/mo for semaglutide, EnhanceMD is one of the more expensive ongoing options in the market. Patients who continue long-term will likely find better value at Oak ($183/mo flat), Tonik ($149/mo), or Maximus ($132.99/mo). EnhanceMD is best used as a low-cost trial entry point, with a planned switch to a more cost-effective ongoing provider if the therapy proves effective.
NAD+ at $84/mo oral is legitimately competitive and a solid reason to choose EnhanceMD if NAD+ is your primary goal alongside a GLP-1 option.
Rating: 7.8/10 — Best for Low-Cost GLP-1 Trial Month + Affordable NAD+